Physician Views: What value for interchangeable biosimilar Humira?

With Boehringer Ingelheim confirming that the FDA has approved Cyltezo as the first interchangeable biosimilar version of AbbVie’s Humira (which will launch with other Humira biosimilars next year) we are running a snap-poll to US-based rheumatologists, gastroenterologists and dermatologists.

Specifically we are asking them…

  • Biosimilar versions of Humira (adalimumab) are expected to launch in the US market next year. Do you intend to proactively prescribe biosimilar Humira?
  • The FDA has now approved one biosimilar Humira product – Boehringer Ingelheim’s Cyltezo – as interchangeable with branded Humira. Do you consider this to be a positive development?
  • In your opinion will FDA-approved interchangeable status positively differentiate Cyltezo versus other (non-interchangeable) biosimilar versions of Humira and encourage physicians to prescribe it more frequently as a result?
  • Cyltezo is a citrate-free product which will be available in 20 mg/0.4mL and 40 mg/0.8 mL pre-filled syringes. By comparison, most branded Humira use now comprises the high concentration formulation (100mg/mL). Will the fact that Cyltezo is not a high concentration formulation meaningfully limit its adoption in your opinion?
  • Do you think the availability of biosimilar Humira products will reduce and/or delay your use of novel mechanism drugs that are not TNF inhibitors (i.e. IL-17, IL-23, JAK inhibitors etc.)?

Poll results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here

See also – ViewPoints: Boehringer secures landmark US biosim approval

To read more Physician Views articles, click here.

Reference Articles